PMID: 15218222Jun 26, 2004Paper

Emergence of nalidixic acid resistance in Shigella sonnei isolated from patients having acute diarrheal disease: report from eastern province of Saudi Arabia

Japanese Journal of Infectious Diseases
Bodh Raj PanhotraKhalifa Al-Mulhim

Abstract

During the 5 years of the study period (October 1999-October 2003), 110 strains of Shigella were isolated from fecal samples of patients having acute diarrheal diseases. Shigella sonnei phase 1 was the most prevalent (88/110, 80.0%) serotype. Resistance to nalidixic acid was not encountered from 1999-2002. Nalidixic acid resistance was observed in 6/13 (46.1%) of the S. sonnei phase 1 strains isolated from April-August 2003. Minimum inhibitory concentration to nalidixic acid among these strains was 48-96 microg/ml. All the six nalidixic acid resistant strains of S. sonnei phase 1 had reduced susceptibility (MIC 0.25 microg/ml) to ciprofloxacin.

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.